A lot of patients with back pain are told that a spinal injection will “send stem cells straight to the disc.” That story is appealing. It’s also not how the body works. Here’s what actually happens — and why the real explanation is more useful, not less.
Spinal anatomy makes direct disc delivery unlikely
For a biologic injected into the paraspinal muscles to reach the inside of a spinal disc, it would have to pass through layers of muscle, cross facet joints, penetrate the ligaments around the spinal cord, traverse the cerebrospinal fluid surrounding the cord, penetrate the outer wall of the disc, and reach the nucleus at the center.
That journey is essentially impossible without intentional intradiscal delivery, which is a very different procedure from a paraspinal application.
What actually happens after a paraspinal biologic application
When a biologic is placed in the paraspinal soft tissue, two things happen.
First: the biologic is absorbed into the local tissue and bloodstream. Some growth factors and signaling molecules can have a mild systemic anti-inflammatory effect. That part is real.
Second — and this is the more important mechanism — the surrounding paraspinal muscles and fascia themselves receive the structural support of the biologic. Those muscles, which are made primarily of collagen, are almost always under chronic protective tension when there’s an underlying disc or facet issue.
The role of paraspinal muscle splinting
When a disc is degenerating or a facet is irritated, the muscles around the spine go into a chronic protective spasm called splinting. That splinting puts additional compressive force directly on the disc and the facet joints. It also generates its own pain.
When a biologic provides structural support to those paraspinal muscles and fascial tissues, the chronic tension can release. As tension releases, the compressive force on the disc decreases. The disc has more room to stabilize. And often, the pain improves — not because the disc itself was directly treated, but because the environment around it was supported.
Why this matters for setting honest expectations
This distinction isn’t a downgrade of the result. The result — reduced pain, improved function, better quality of life — can be very real. The point is that the explanation should match the biology.
When patients are told stem cells will rebuild their disc, they often expect a structural change to show up on imaging that may not show up. When patients understand that the goal is supporting the connective tissue environment around the spine — reducing tension, supplying collagen building blocks, calming inflammation — the actual result tends to align with expectations far better.
Where biologics may have a meaningful role in spine care
The annulus fibrosus — the outer ring of the disc — is Type 1 collagen. That is exactly the structural composition that collagen-rich biologics are designed to support. When there’s an annular tear, the disc’s naturally limited blood supply makes self-repair difficult.
Protocols that supply Type 1 and Type 3 collagen to the tissue surrounding a disc injury aren’t claiming to cure disc disease. They’re supplying the specific structural building blocks that the outer disc wall is made of — building blocks the body cannot adequately deliver on its own due to the disc’s vascularity. That’s a defensible biological rationale, and it’s very different from “stem cells will reach your disc.”
Why honest framing builds trust
Our medical team has a working principle on this: good results deserve accurate explanations. When patients understand what their body is actually doing in response to a biologic, they trust the process more, evaluate outcomes more realistically, and feel respected as partners in their own care.
That trust matters. It’s also the antidote to the broader credibility problem regenerative medicine has accumulated from years of overclaiming. Honest mechanisms protect patients — and they protect the field.
REQUIRED DISCLAIMER
Educational content only. The information presented in this article is for general informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. RegenHaus uses 361 HCT/P regenerative biologics, which are not FDA-approved to treat or cure any condition. Individual results vary. Please consult a licensed medical provider before considering any therapy or making changes to your health regimen.
